MYO Quote, Financials, Valuation and Earnings

Electromed has a net margin of -2.16% compared to Myomo's net margin of 12.11%. Myomo's return on equity of -48.64% beat Electromed's return on equity of 15.91%.

Myomo has a consensus price target of $9.05, signalling upside risk potential of 182.81%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 66.14%. Given that Myomo has higher upside potential than Electromed, analysts believe Myomo is more attractive than Electromed.

Myomo has a beta of 1.633, which suggesting that the stock is 63.336% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are smaller than Electromed quarterly revenues of $16.3M. Myomo's net income of -$260.1K is lower than Electromed's net income of $2M. Notably, Myomo's price-to-earnings ratio is -- while Electromed's PE ratio is 29.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 3.71x versus 3.34x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -2.16% compared to Myomo's net margin of -16.69%. Myomo's return on equity of -48.64% beat IRIDEX's return on equity of -157.91%.

Myomo has a consensus price target of $9.05, signalling upside risk potential of 182.81%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 73.91%. Given that Myomo has higher upside potential than IRIDEX, analysts believe Myomo is more attractive than IRIDEX.

Myomo has a beta of 1.633, which suggesting that the stock is 63.336% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are larger than IRIDEX quarterly revenues of $11.6M. Myomo's net income of -$260.1K is higher than IRIDEX's net income of -$1.9M. Notably, Myomo's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 3.71x versus 0.39x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -2.16% compared to Myomo's net margin of -118.53%. Myomo's return on equity of -48.64% beat Stereotaxis's return on equity of -139.2%.

Myomo has a consensus price target of $9.05, signalling upside risk potential of 182.81%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 111.27%. Given that Myomo has higher upside potential than Stereotaxis, analysts believe Myomo is more attractive than Stereotaxis.

Myomo has a beta of 1.633, which suggesting that the stock is 63.336% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are larger than Stereotaxis quarterly revenues of $6.3M. Myomo's net income of -$260.1K is higher than Stereotaxis's net income of -$7.5M. Notably, Myomo's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 3.71x versus 6.74x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.

Viemed Healthcare has a net margin of -2.16% compared to Myomo's net margin of 7.11%. Myomo's return on equity of -48.64% beat Viemed Healthcare's return on equity of 9.21%.

Myomo has a consensus price target of $9.05, signalling upside risk potential of 182.81%. On the other hand Viemed Healthcare has an analysts' consensus of $12.83 which suggests that it could grow by 103.06%. Given that Myomo has higher upside potential than Viemed Healthcare, analysts believe Myomo is more attractive than Viemed Healthcare.

Myomo has a beta of 1.633, which suggesting that the stock is 63.336% more volatile than S&P 500. In comparison Viemed Healthcare has a beta of 1.492, suggesting its more volatile than the S&P 500 by 49.165%.

Myomo has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viemed Healthcare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Myomo pays -- of its earnings as a dividend. Viemed Healthcare pays out -- of its earnings as a dividend.

Myomo quarterly revenues are $12.1M, which are smaller than Viemed Healthcare quarterly revenues of $60.7M. Myomo's net income of -$260.1K is lower than Viemed Healthcare's net income of $4.3M. Notably, Myomo's price-to-earnings ratio is -- while Viemed Healthcare's PE ratio is 22.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Myomo is 3.71x versus 1.15x for Viemed Healthcare. Usually stocks with elevated PS ratios are considered overvalued.